Myocyte enhancer factor 2D (MEF2D)

Myocyte enhancer factor 2D (MEF2D) is a member of the MEF2 family of transcription factors, which are part of the MADS-box family involved in a wide array of developmental processes. MEF2D regulates gene expression by binding to A/T-rich DNA sequences within the promoter regions of target genes, often in cooperation with other transcription factors such as myogenic regulatory factors. It is crucial for muscle and neuronal cell differentiation, as well as B-cell development in the immune system[2][3][6]. MEF2D contains a conserved N-terminal MADS-box and MEF2 domain for DNA binding and dimerization, with a variable C-terminal transactivation/repression region that is regulated by alternative splicing and phosphorylation. Abnormal MEF2D fusions, such as MEF2D-HNRNPUL1 and MEF2D-BCL9, are recurrent genetic lesions in B-cell precursor acute lymphoblastic leukemia (BCP-ALL) and confer poor prognosis. In preclinical studies, histone deacetylase inhibitors like panobinostat can suppress aberrant MEF2D fusion-driven gene expression, highlighting MEF2D as a potential therapeutic target in specific leukemia subtypes[1][4][6].

Other names

Myocyte-specific enhancer factor 2DMADS box transcription enhancer factor 2 polypeptide DMEF2D (gene/protein symbol)Myocyte enhancer factor D

Inhibition of histone deacetylase (HDAC) activity to suppress MEF2D fusion-driven transcription